Docetaxel was the first agent to show survival benefit in metastatic Hormone Refractory Prostate Cancer (mHRPC) and since approval by NICE in 2006 (TA101) has for many years been the mainstay of treatment.
To appraise the clinical and cost effectiveness of cabazitaxel within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen.
|Place of Publication||National Institute for Health and Care Excellence|
|Publisher||National Institute for Health and Care Excellence|
|Number of pages||36|
|Publication status||Published - 01 Jun 2016|